Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasms 2Hematologic Neoplasms 2Stomach Neoplasms 1Sarcoma 1Neuroblastoma 1Lymphoproliferative Disorders 1Glioma 1

Interventions

trametinib 3dabrafenib 3Paclitaxel 2Nivolumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sargramostim 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olutasidenib 1liposomal doxorubicin 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1entinostat 1defactinib 1copanlisib 1cobimetinib 1carboxyamido-triazole 1capmatinib 1capivasertib 1binimetinib 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × capmatinib × Other hematologic neoplasm × Clear all
NCT06988475 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡